BJH - volume 6, issue Abstract Book BHS, january 2015
B. Heyrman MD, A. De Becker MD, K. Fostier MD, F. Trullemans , R. Schots MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
X. Galloo , C. Caron , L. Pipeleers , K. Wissing , K. Fostier MD, F. Trullemans , C. Tielemans , R. Schots MD, PhD, A. De Becker MD
BJH - volume 4, issue 1, march 2013
K. Fostier MD, A. De Becker MD, R. Schots MD, PhD
The immunomodulatory drugs (IMiDs) are a class of orally available compounds which are licensed for the treatment of multiple myeloma (thalidomide, lenalidomide) and transfusion-dependent low- and intermediate-risk myelodysplasia (MDS) with deletion of long arm of chromosome 5 (lenalidomide). Pomalidomide, a novel second generation IMiD, is entering clinical trials and seems to further broaden the therapeutic spectrum of these already pleiotropic drugs. Here we summarise new insights into the mechanism of action of IMiDs as well as new developments related to their clinical use, as maintenance therapy in multiple myeloma (MM), in the treatment of myeloproliferative neoplasm- associated myelofibrosis, other types of MDS, chronic lymphocytic leukaemia (CLL) and sickle cell disease (SCD).
(BELG J HEMATOL 2013;1:21–28)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
C. Caron , A. De Becker MD, K. Fostier MD, M. De Waele , H. De Raeve MD, PhD, R. Schots MD, PhD, F. Trullemans
BJH - 2013, issue BHS Abstractbook, january 2013
N. De Beule MD, PhD, K. Fostier MD, A. De Becker MD, C. Caron , F. Trullemans , R. Schots MD, PhD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
